|
Andrx rallies on settlement of patent dispute (ADRX) by Michael Baron NEW YORK (CBS.MW) -- Andrx (ADRX) shares surged more than 12 percent to $21 after the company said it has agreed to settle patent infringement litigation related to a generic version of Glucotrol XL, a drug that helps control blood sugar levels for people with type 2 diabetes. Pfizer and Alza have agreed to dismiss their lawsuits against Andrx, and Andrx will receive a royalty-bearing sub-license under relevant Alza patents. This will allow it to manufacture and market products under its abbreviated new drug application for Glucotrol. Additionally, no later than January 1, Pfizer will supply Andrx with all or any strength of its product for sale by Andrx as an authorized generic under Pfizer`s own new drug application. |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | dosto (05.09.03 18:39:09) |
| Beitrag: | 92 von 125 (ID:10659698) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |